Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
March 09 2017 - 9:00AM
Celsion Corporation (NASDAQ:CLSN) announced today that the Company
will host a conference call to discuss year-end 2016 financial
results and provide an update on its development programs for
ThermoDox®, its proprietary heat-activated liposomal encapsulation
of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated
into a nanoparticle with a non-viral delivery system at 11:00 a.m.
ET on Thursday, March 16, 2017. To participate in the call,
interested parties may dial 1-888-490-2763 (Toll-Free/North
America) or 1-719-325-2481 (International/Toll) and ask for the
Celsion Corporation 4th Quarter 2016 Earnings Call (Conference
Code: 8052561) to register ten minutes before the call is scheduled
to begin. The call will also be broadcast live on the internet at
www.celsion.com.
The call will be archived for replay on
Thursday, March 16, 2017 and will remain available until Thursday,
March 30, 2017. The replay can be accessed at 1-888-203-1112
(Toll-Free/North America) or 1-719-457-0820 (International/Toll)
using Conference Code: 8052561. An audio replay of the call will
also be available on the Company’s website, www.celsion.com, for 30
days after 2:00 p.m. ET on Thursday, March 16, 2017.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in Phase II development for the treatment of
recurrent chest wall breast cancer. The pipeline also
includes GEN-1, a DNA-based immunotherapy for the localized
treatment of ovarian and brain cancers. Celsion has two
platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlas and TheraSilence. For more
information on Celsion, visit our website: www.celsion.com.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2024 to May 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From May 2023 to May 2024